Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
Despite progress in understanding the pathogenesis of atherosclerosis, the development of effective therapeutic strategies is a challenging task that requires more research to attain its full potential. This review discusses current pharmacotherapy in atherosclerosis and explores the potential of so...
Main Authors: | Ana Clara Aprotosoaie, Alexandru-Dan Costache, Irina-Iuliana Costache |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/4/722 |
Similar Items
-
Pharmacological Therapy for COVID-19: Where Are We Now and Where Are We Going?
by: Baha Eldin Hassan Juma, et al.
Published: (2020-04-01) -
Atherosclerosis in HIV Patients: What Do We Know so Far?
by: Anastasia V. Poznyak, et al.
Published: (2022-02-01) -
Overactive Bladder: Where We Are and Where We Are Going
by: Charan S. Mohan, et al.
Published: (2021-09-01) -
New Insights into the Role of Inflammation in the Pathogenesis of Atherosclerosis
by: Meng-Yu Wu, et al.
Published: (2017-09-01) -
Hypertriglyceridemia and atherosclerosis
by: Jia Peng, et al.
Published: (2017-12-01)